Christer Einvik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christer Einvik has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Trond Flægstad
Pediatric Research Group, Department of Clinical Medicine, Faculty of Health Science, UiT—The Arctic University of Norway, Tromsø, Norway
8 shared publicationsCecilie Løkke
Affiliation Research Group for Child and Adolescent Health, Department of Clinical Medicine, Faculty of Health Sciences, UiT-The Arctic University of Norway, Tromsø, Norway
7 shared publicationsPeter Utnes
Department of Pediatrics, Division of Child and Adolescent Health, UNN - University Hospital of North-Norway, Tromsø, Norway
3 shared publicationsØyvind H. Hald
Department of Pediatrics, Division of Child and Adolescent Health, UNN - University Hospital of North-Norway, NO-9038, Tromsø, Norway
3 shared publications- Cecilie Løkke
Department of Pediatrics, University Hospital of North-Norway, 9038 Tromsø, Norway
2 shared publications Lotte Olsen
Pediatric Research Group, Department of Clinical Medicine, Faculty of Health Science, UiT—The Arctic University of Norway, Tromsø, Norway
2 shared publications
Latest Publications
- Open Access
- 11 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0339960
A gene-specific RNA enrichment protocol for nanopore direct-RNA sequencing
Oxford Nanopore direct-RNA sequencing, a third-generation sequencing technology, allows for the analysis of native RNA molecules in their natural cellular state. However, cellular RNA is predominantly composed of ribosomal RNA and transcripts from ubiquitously expressed housekeeping genes, which limits the coverage of transcripts from lowly expressed genes. To address this limitation, targeted sequencing can be employed to enrich read coverage by focusing specifically on genes of interest. Here, we present a step-by-step protocol for gene-specific RNA enrichment followed by Oxford Nanopore direct-RNA sequencing. The enrichment protocol utilizes biotinylated DNA capture probes complementary to the target gene. Following in-solution hybridization of probes to total RNA, a series of stringent washes is applied before elution of the enriched RNA sample. The protocol describes all steps from isolation of cellular total RNA to bioinformatic analyses of raw sequencing data. As a proof of concept, capture probes were designed to specifically enrich all RNA species encoded by the MYCN oncogene. The enrichment protocol successfully isolated RNAs from the MYCN gene, achieving a purification factor of 4.8 × 10 3 . Direct-RNA sequencing of the enriched RNA sample revealed that 65% of the primary mapped reads aligned to MYCN transcripts. We also include a more thorough analysis of the most abundant non-target mapped reads and unmapped reads. This protocol proves to be highly effective in removing unwanted RNA species, delivering robust enrichment for the target gene, and significantly enhancing the efficiency of long-read direct-RNA sequencing.
- 11 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0339960
Open AccessA gene-specific RNA enrichment protocol for nanopore direct-RNA sequencing
Oxford Nanopore direct-RNA sequencing, a third-generation sequencing technology, allows for the analysis of native RNA molecules in their natural cellular state. However, cellular RNA is predominantly composed of ribosomal RNA and transcripts from ubiquitously expressed housekeeping genes, which limits the coverage of transcripts from lowly expressed genes. To address this limitation, targeted sequencing can be employed to enrich read coverage by focusing specifically on genes of interest. Here, we present a step-by-step protocol for gene-specific RNA enrichment followed by Oxford Nanopore direct-RNA sequencing. The enrichment protocol utilizes biotinylated DNA capture probes complementary to the target gene. Following in-solution hybridization of probes to total RNA, a series of stringent washes is applied before elution of the enriched RNA sample. The protocol describes all steps from isolation of cellular total RNA to bioinformatic analyses of raw sequencing data. As a proof of concept, capture probes were designed to specifically enrich all RNA species encoded by the MYCN oncogene. The enrichment protocol successfully isolated RNAs from the MYCN gene, achieving a purification factor of 4.8 × 10 3 . Direct-RNA sequencing of the enriched RNA sample revealed that 65% of the primary mapped reads aligned to MYCN transcripts. We also include a more thorough analysis of the most abundant non-target mapped reads and unmapped reads. This protocol proves to be highly effective in removing unwanted RNA species, delivering robust enrichment for the target gene, and significantly enhancing the efficiency of long-read direct-RNA sequencing.
- Open Access
- 24 March 2023
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 11
Hsa-miR-323a-3p functions as a tumor suppressor and targets STAT3 in neuroblastoma cells
Background: Studies conducted in the last decades have revealed a role for the non-coding microRNAs (miRNAs) in cancer development and progression. Several miRNAs within the chromosome region 14q32, a region commonly deleted in cancers, are associated with poor clinical outcome in the childhood cancer neuroblastoma. We have previously identified miR-323a-3p from this region to be downregulated in chemotherapy treated neuroblastoma cells compared to pre-treatment cells from the same patients. Furthermore, in neuroblastoma tumors, this miRNA is downregulated in advanced stage 4 disease compared to stage 1–2. In this study, we attempt to delineate the unknown functional roles of miR-323a-3p in neuroblastoma.Methods: Synthetic miRNA mimics were used to overexpress miR-323a-3p in neuroblastoma cell lines. To investigate the functional roles of miR-323a-3p, cell viability assay, flow cytometry, reverse transcription-quantitative polymerase chain reaction, luciferase reporter assay and western blot were conducted on the neuroblastoma cell lines Kelly, SH-SY5Y and SK-N-BE(2)-C.Results: Ectopic expression of miR-323a-3p resulted in marked reduction of cell viability in Kelly, SH-SY5Y and SK-N-BE(2)-C by causing G1-cell cycle arrest in Kelly and SH-SY5Y and apoptosis in all the cell lines tested. Furthermore, mRNA and protein levels of signal transducer and activator of transcription 3 (STAT3) were reduced upon miR-323a-3p overexpression. A direct binding of the miR-323a-3p to the 3′UTR of STAT3 was experimentally validated by luciferase reporter assay, where miR-323a-3p reduced luminescent signal from full length STAT3 3′UTR luciferase reporter, but not from a reporter with mutation in the predicted seed sequence.Conclusions: miR-323a-3p inhibits growth of neuroblastoma cell lines through G1-cell cycle arrest and apoptosis, and the well-known oncogene STAT3 is a direct target of this miRNA.
- 24 March 2023
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 11
Open AccessHsa-miR-323a-3p functions as a tumor suppressor and targets STAT3 in neuroblastoma cells
Background: Studies conducted in the last decades have revealed a role for the non-coding microRNAs (miRNAs) in cancer development and progression. Several miRNAs within the chromosome region 14q32, a region commonly deleted in cancers, are associated with poor clinical outcome in the childhood cancer neuroblastoma. We have previously identified miR-323a-3p from this region to be downregulated in chemotherapy treated neuroblastoma cells compared to pre-treatment cells from the same patients. Furthermore, in neuroblastoma tumors, this miRNA is downregulated in advanced stage 4 disease compared to stage 1–2. In this study, we attempt to delineate the unknown functional roles of miR-323a-3p in neuroblastoma.Methods: Synthetic miRNA mimics were used to overexpress miR-323a-3p in neuroblastoma cell lines. To investigate the functional roles of miR-323a-3p, cell viability assay, flow cytometry, reverse transcription-quantitative polymerase chain reaction, luciferase reporter assay and western blot were conducted on the neuroblastoma cell lines Kelly, SH-SY5Y and SK-N-BE(2)-C.Results: Ectopic expression of miR-323a-3p resulted in marked reduction of cell viability in Kelly, SH-SY5Y and SK-N-BE(2)-C by causing G1-cell cycle arrest in Kelly and SH-SY5Y and apoptosis in all the cell lines tested. Furthermore, mRNA and protein levels of signal transducer and activator of transcription 3 (STAT3) were reduced upon miR-323a-3p overexpression. A direct binding of the miR-323a-3p to the 3′UTR of STAT3 was experimentally validated by luciferase reporter assay, where miR-323a-3p reduced luminescent signal from full length STAT3 3′UTR luciferase reporter, but not from a reporter with mutation in the predicted seed sequence.Conclusions: miR-323a-3p inhibits growth of neuroblastoma cell lines through G1-cell cycle arrest and apoptosis, and the well-known oncogene STAT3 is a direct target of this miRNA.
- Open Access
- 1 January 2019
- Published by SAGE Publications in Cancer Informatics
- Vol. 18
Clinically Relevant Biomarker Discovery in High-Risk Recurrent Neuroblastoma
Neuroblastoma is a pediatric cancer of the developing sympathetic nervous system. High-risk neuroblastoma patients typically undergo an initial remission in response to treatment, followed by recurrence of aggressive tumors that have become refractory to further treatment. The need for biomarkers that can select patients not responding well to therapy in an early phase is therefore needed. In this study, we used next generation sequencing technology to determine the expression profiles in high-risk neuroblastoma cell lines established before and after therapy. Using partial least squares-discriminant analysis (PLS-DA) with least absolute shrinkage and selection operator (LASSO) and leave-one-out cross-validation, we identified a panel of 55 messenger RNAs and 17 long non-coding RNAs (lncRNAs) which were significantly altered in the expression between cell lines isolated from primary and recurrent tumors. From a neuroblastoma patient cohort, we found 20 of the 55 protein-coding genes to be differentially expressed in patients with unfavorable compared with favorable outcome. We further found a twofold increase or decrease in hazard ratios in these genes when comparing patients with unfavorable and favorable outcome. Gene set enrichment analysis (GSEA) revealed that these genes were involved in proliferation, differentiation and regulated by Polycomb group (PcG) proteins. Of the 17 lncRNAs, 3 upregulated (NEAT1, SH3BP5-AS1, NORAD) and 3 downregulated lncRNAs (DUBR, MEG3, DHRS4-AS1) were also found to be differentially expressed in favorable compared with unfavorable outcome. Moreover, using expression profiles on both miRNAs and mRNAs in the same cohort of cell lines, we found 13 downregulated and 18 upregulated experimentally observed miRNA target genes targeted by miR-21, -424 and -30e, -29b, -138, -494, -181a, -34a, -29b, respectively. The advantage of analyzing biomarkers in a clinically relevant neuroblastoma model system enables further studies on the effect of individual genes upon gene perturbation. In summary, this study identified several genes, which may aid in the prediction of response to therapy and tumor recurrence.
- 1 January 2019
- Published by SAGE Publications in Cancer Informatics
- Vol. 18
Open AccessClinically Relevant Biomarker Discovery in High-Risk Recurrent Neuroblastoma
Neuroblastoma is a pediatric cancer of the developing sympathetic nervous system. High-risk neuroblastoma patients typically undergo an initial remission in response to treatment, followed by recurrence of aggressive tumors that have become refractory to further treatment. The need for biomarkers that can select patients not responding well to therapy in an early phase is therefore needed. In this study, we used next generation sequencing technology to determine the expression profiles in high-risk neuroblastoma cell lines established before and after therapy. Using partial least squares-discriminant analysis (PLS-DA) with least absolute shrinkage and selection operator (LASSO) and leave-one-out cross-validation, we identified a panel of 55 messenger RNAs and 17 long non-coding RNAs (lncRNAs) which were significantly altered in the expression between cell lines isolated from primary and recurrent tumors. From a neuroblastoma patient cohort, we found 20 of the 55 protein-coding genes to be differentially expressed in patients with unfavorable compared with favorable outcome. We further found a twofold increase or decrease in hazard ratios in these genes when comparing patients with unfavorable and favorable outcome. Gene set enrichment analysis (GSEA) revealed that these genes were involved in proliferation, differentiation and regulated by Polycomb group (PcG) proteins. Of the 17 lncRNAs, 3 upregulated (NEAT1, SH3BP5-AS1, NORAD) and 3 downregulated lncRNAs (DUBR, MEG3, DHRS4-AS1) were also found to be differentially expressed in favorable compared with unfavorable outcome. Moreover, using expression profiles on both miRNAs and mRNAs in the same cohort of cell lines, we found 13 downregulated and 18 upregulated experimentally observed miRNA target genes targeted by miR-21, -424 and -30e, -29b, -138, -494, -181a, -34a, -29b, respectively. The advantage of analyzing biomarkers in a clinically relevant neuroblastoma model system enables further studies on the effect of individual genes upon gene perturbation. In summary, this study identified several genes, which may aid in the prediction of response to therapy and tumor recurrence.
- Open Access
- 12 December 2018
- Published by Springer Nature in Oncogene
- Vol. 38 (15) , 2800-2813
Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma
Abnormal increases in nucleolar size and number caused by dysregulation of ribosome biogenesis has emerged as a hallmark in the majority of spontaneous cancers. The observed ribosome hyperactivity can be directly induced by the MYC transcription factors controlling the expression of RNA and protein components of the ribosome. Neuroblastoma, a highly malignant childhood tumor of the sympathetic nervous system, is frequently characterized by MYCN gene amplification and high expression of MYCN and c-MYC signature genes. Here, we show a strong correlation between high-risk disease, MYCN expression, poor survival, and ribosome biogenesis in neuroblastoma patients. Treatment of neuroblastoma cells with quarfloxin or CX-5461, two small molecule inhibitors of RNA polymerase I, suppressed MycN expression, induced DNA damage, and activated p53 followed by cell cycle arrest or apoptosis. CX-5461 repressed the growth of established MYCN-amplified neuroblastoma xenograft tumors in nude mice. These findings suggest that inhibition of ribosome biogenesis represent new therapeutic opportunities for children with high-risk neuroblastomas expressing high levels of Myc.
- 12 December 2018
- Published by Springer Nature in Oncogene
- Vol. 38 (15) , 2800-2813
Open AccessInhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma
Abnormal increases in nucleolar size and number caused by dysregulation of ribosome biogenesis has emerged as a hallmark in the majority of spontaneous cancers. The observed ribosome hyperactivity can be directly induced by the MYC transcription factors controlling the expression of RNA and protein components of the ribosome. Neuroblastoma, a highly malignant childhood tumor of the sympathetic nervous system, is frequently characterized by MYCN gene amplification and high expression of MYCN and c-MYC signature genes. Here, we show a strong correlation between high-risk disease, MYCN expression, poor survival, and ribosome biogenesis in neuroblastoma patients. Treatment of neuroblastoma cells with quarfloxin or CX-5461, two small molecule inhibitors of RNA polymerase I, suppressed MycN expression, induced DNA damage, and activated p53 followed by cell cycle arrest or apoptosis. CX-5461 repressed the growth of established MYCN-amplified neuroblastoma xenograft tumors in nude mice. These findings suggest that inhibition of ribosome biogenesis represent new therapeutic opportunities for children with high-risk neuroblastomas expressing high levels of Myc.
- Open Access
- 11 September 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 16 (5) , 6786-6794
Hsa‑miR‑376c‑3p targets Cyclin D1 and induces G1‑cell cycle arrest in neuroblastoma cells
High‑risk neuroblastoma is the most aggressive form of cancer in children. The estimated survival of children with high‑risk neuroblastoma is 40‑50% compared with low and intermediate risk neuroblastoma, which is >98 and 90‑95%, respectively. In addition, patients with high‑risk neuroblastoma often experience relapse following intensive treatments with standard chemotherapeutic drugs. Therefore alternative strategies are required to address this problem. MicroRNAs (miRNAs/miRs) are small, endogenously expressed non‑coding RNAs, which when deregulated have been demonstrated to serve significant roles in the tumorigenesis of a number of different types of cancer. Results from a previous deep sequencing study identified 22 downregulated miRNAs from the 14q32 miRNA cluster differentially expressed in neuroblastoma cell lines isolated from 6 patients at diagnosis and at relapse following intensive treatments. miR‑376c‑3p is one of the 22 miRNAs that was downregulated in the majority of the cell lines isolated from patients post treatment. The present study employed reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) to quantify the basic expression of miR‑376c‑3p in 6 neuroblastoma cell lines. The functional role of miR‑376c‑3p in the neuroblastoma cell lines was evaluated by alamar blue‑cell viability and propidium iodide‑flow cytometric assays. In addition, luciferase reporter assays, RT‑qPCR and western blotting were performed to identify and quantify the targets of miR‑376c‑3p in neuroblastoma cell lines. Ectopic expression of miR‑376c‑3p led to significant inhibition of cell viability and G1‑cell cycle arrest in multiple neuroblastoma cell lines by reducing the expression of cyclin D1, an oncogene critical for neuroblastoma pathogenesis. The results of the present study provide novel insights into the functional role of miR‑376c‑3p and suggest new approaches for the treatment of neuroblastoma.
- 11 September 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 16 (5) , 6786-6794
Open AccessHsa‑miR‑376c‑3p targets Cyclin D1 and induces G1‑cell cycle arrest in neuroblastoma cells
High‑risk neuroblastoma is the most aggressive form of cancer in children. The estimated survival of children with high‑risk neuroblastoma is 40‑50% compared with low and intermediate risk neuroblastoma, which is >98 and 90‑95%, respectively. In addition, patients with high‑risk neuroblastoma often experience relapse following intensive treatments with standard chemotherapeutic drugs. Therefore alternative strategies are required to address this problem. MicroRNAs (miRNAs/miRs) are small, endogenously expressed non‑coding RNAs, which when deregulated have been demonstrated to serve significant roles in the tumorigenesis of a number of different types of cancer. Results from a previous deep sequencing study identified 22 downregulated miRNAs from the 14q32 miRNA cluster differentially expressed in neuroblastoma cell lines isolated from 6 patients at diagnosis and at relapse following intensive treatments. miR‑376c‑3p is one of the 22 miRNAs that was downregulated in the majority of the cell lines isolated from patients post treatment. The present study employed reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) to quantify the basic expression of miR‑376c‑3p in 6 neuroblastoma cell lines. The functional role of miR‑376c‑3p in the neuroblastoma cell lines was evaluated by alamar blue‑cell viability and propidium iodide‑flow cytometric assays. In addition, luciferase reporter assays, RT‑qPCR and western blotting were performed to identify and quantify the targets of miR‑376c‑3p in neuroblastoma cell lines. Ectopic expression of miR‑376c‑3p led to significant inhibition of cell viability and G1‑cell cycle arrest in multiple neuroblastoma cell lines by reducing the expression of cyclin D1, an oncogene critical for neuroblastoma pathogenesis. The results of the present study provide novel insights into the functional role of miR‑376c‑3p and suggest new approaches for the treatment of neuroblastoma.
- Open Access
- 6 April 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (26) , 18160-18179
MicroRNA-193b-3p represses neuroblastoma cell growth via downregulation of Cyclin D1, MCL-1 and MYCN
Neuroblastoma is the most common diagnosed tumor in infants and the second most common extracranial tumor of childhood. The survival rate of patients with high-risk neuroblastoma is still very low despite intensive multimodal treatments. Therefore, new treatment strategies are needed. In recent years, miRNA-based anticancer therapy has received growing attention. Advances in this novel treatment strategy strongly depends on the identification of candidate miRNAs with broad-spectrum antitumor activity. Here, we identify miR-193b as a miRNA with tumor suppressive properties. We show that miR-193b is expressed at low levels in neuroblastoma cell lines and primary tumor samples. Introduction of miR-193b mimics into nine neuroblastoma cell lines with distinct genetic characteristics significantly reduces cell growth in vitro independent of risk factors such as p53 functionality or MYCN amplification. Functionally, miR-193b induces a G1 cell cycle arrest and cell death in neuroblastoma cell lines by reducing the expression of MYCN, Cyclin D1 and MCL-1, three important oncogenes in neuroblastoma of which inhibition has shown promising results in preclinical testing. Therefore, we suggest that miR-193b may represent a new candidate for miRNA-based anticancer therapy in neuroblastoma.
- 6 April 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (26) , 18160-18179
Open AccessMicroRNA-193b-3p represses neuroblastoma cell growth via downregulation of Cyclin D1, MCL-1 and MYCN
Neuroblastoma is the most common diagnosed tumor in infants and the second most common extracranial tumor of childhood. The survival rate of patients with high-risk neuroblastoma is still very low despite intensive multimodal treatments. Therefore, new treatment strategies are needed. In recent years, miRNA-based anticancer therapy has received growing attention. Advances in this novel treatment strategy strongly depends on the identification of candidate miRNAs with broad-spectrum antitumor activity. Here, we identify miR-193b as a miRNA with tumor suppressive properties. We show that miR-193b is expressed at low levels in neuroblastoma cell lines and primary tumor samples. Introduction of miR-193b mimics into nine neuroblastoma cell lines with distinct genetic characteristics significantly reduces cell growth in vitro independent of risk factors such as p53 functionality or MYCN amplification. Functionally, miR-193b induces a G1 cell cycle arrest and cell death in neuroblastoma cell lines by reducing the expression of MYCN, Cyclin D1 and MCL-1, three important oncogenes in neuroblastoma of which inhibition has shown promising results in preclinical testing. Therefore, we suggest that miR-193b may represent a new candidate for miRNA-based anticancer therapy in neuroblastoma.
- 17 December 2015
- Published by Elsevier in Cancer Letters
- Vol. 372 (1) , 128-136
Next generation sequencing of microRNAs from isogenic neuroblastoma cell lines isolated before and after treatment
- 17 December 2015
- Published by Elsevier in Cancer Letters
- Vol. 372 (1) , 128-136
Next generation sequencing of microRNAs from isogenic neuroblastoma cell lines isolated before and after treatment
- 1 May 2015
- Vol. 35 (5) , 2521-30
Exosome-like Extracellular Vesicles from MYCN-amplified Neuroblastoma Cells Contain Oncogenic miRNAs.
In recent years, evidence has accumulated indicating that both normal and cancer cells communicate via the release and delivery of macromolecules packed into extracellular membrane vesicles. We isolated nano-sized extracellular vesicles from MYCN-amplified neuroblastoma cell lines using ultracentrifugation and exosome precipitation (Exoquick) protocols. These vesicles were characterized by transmission electron microscopy (TEM), nanoparticle tracking analysis and western blotting. Exosomal miRNA profiles were obtained using a reverse transcription-polymerase chain reaction (RT-PCR) ready-to-use panel measuring a total of 742 miRNAs. In this study, we showed that MYCN-amplified neuroblastoma cell lines secrete populations of miRNAs inside small exosome-like vesicular particles. These particles were shown to be taken-up by recipient cells. By profiling the miRNA content, we demonstrated high expression of a group of established oncomirs in exosomes from two MYCN-amplified neuroblastoma cell lines. Despite the fact that other studies have demonstrated the ability of exosomal miRNAs both to repress mRNA targets and to stimulate Toll-like receptor-8 (TLR8) signaling in recipient cells, we did not observe these effects with exosomes from MYCN-amplified neuroblastoma cells. However, functional enrichment analysis reveals that mRNA targets of highly expressed exosomal miRNAs are associated with a range of cellular and molecular functions related to cell growth and cell death. MYCN-amplified neuroblastoma cell lines secrete exosome-like particles containing oncogenic miRNAs. This work showed for the first time that neuroblastoma cells secrete exosome-like particles containing miRNAs with potential roles in cancer progression. These findings indicate a new way for MYCN-amplified neuroblastoma cells to interact with the tumor environment.
- 1 May 2015
- Vol. 35 (5) , 2521-30
Exosome-like Extracellular Vesicles from MYCN-amplified Neuroblastoma Cells Contain Oncogenic miRNAs.
In recent years, evidence has accumulated indicating that both normal and cancer cells communicate via the release and delivery of macromolecules packed into extracellular membrane vesicles. We isolated nano-sized extracellular vesicles from MYCN-amplified neuroblastoma cell lines using ultracentrifugation and exosome precipitation (Exoquick) protocols. These vesicles were characterized by transmission electron microscopy (TEM), nanoparticle tracking analysis and western blotting. Exosomal miRNA profiles were obtained using a reverse transcription-polymerase chain reaction (RT-PCR) ready-to-use panel measuring a total of 742 miRNAs. In this study, we showed that MYCN-amplified neuroblastoma cell lines secrete populations of miRNAs inside small exosome-like vesicular particles. These particles were shown to be taken-up by recipient cells. By profiling the miRNA content, we demonstrated high expression of a group of established oncomirs in exosomes from two MYCN-amplified neuroblastoma cell lines. Despite the fact that other studies have demonstrated the ability of exosomal miRNAs both to repress mRNA targets and to stimulate Toll-like receptor-8 (TLR8) signaling in recipient cells, we did not observe these effects with exosomes from MYCN-amplified neuroblastoma cells. However, functional enrichment analysis reveals that mRNA targets of highly expressed exosomal miRNAs are associated with a range of cellular and molecular functions related to cell growth and cell death. MYCN-amplified neuroblastoma cell lines secrete exosome-like particles containing oncogenic miRNAs. This work showed for the first time that neuroblastoma cells secrete exosome-like particles containing miRNAs with potential roles in cancer progression. These findings indicate a new way for MYCN-amplified neuroblastoma cells to interact with the tumor environment.
- Open Access
- 7 June 2011
- Published by Springer Nature in British Journal of Cancer
- Vol. 105 (2) , 296-303
Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma
Background: Methods: Results: Conclusion:
- 7 June 2011
- Published by Springer Nature in British Journal of Cancer
- Vol. 105 (2) , 296-303
Open AccessTumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma
Background: Methods: Results: Conclusion:
- 13 May 2011
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 32 (7) , 1005-1012
MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma
The MYCN oncogene is frequently amplified in neuroblastoma. It is one of the most consistent markers of bad prognosis for this disease. Dickkopf-3 (DKK3) is a secreted protein of the DKK family of Wnt regulators. It functions as a tumor suppressor in a range of cancers, including neuroblastoma. MYCN was recently found to downregulate DKK3 mRNA. In this study, we show that MYCN knockdown in MYCN-amplified (MNA) neuroblastoma cell lines increases secretion of endogenous DKK3 to the culture media.
- 13 May 2011
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 32 (7) , 1005-1012
MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma
The MYCN oncogene is frequently amplified in neuroblastoma. It is one of the most consistent markers of bad prognosis for this disease. Dickkopf-3 (DKK3) is a secreted protein of the DKK family of Wnt regulators. It functions as a tumor suppressor in a range of cancers, including neuroblastoma. MYCN was recently found to downregulate DKK3 mRNA. In this study, we show that MYCN knockdown in MYCN-amplified (MNA) neuroblastoma cell lines increases secretion of endogenous DKK3 to the culture media.